This site is intended for health professionals only

Home / News / Dispensing / Billions to be lost by drug companies by end of decade

Billions to be lost by drug companies by end of decade


12 Dec 2014

Pharmaceutical companies will lose more than £40bn by 2019, due to patents on drugs expiring.

It is claimed companies such as Otsuka, Eli Lilly and AstraZeneca (AZ) will be affected the most, especially in the central nervous system (CNS) medication sector.

GlobalData analyst for healthcare industry dynamics, Adam Dion, said: “AZ’s CNS segment has been bleeding sales as a result of the company losing its patent on Seroquel, a treatment for bipolar disorder, allowing for cheaper generic alternatives.”

It is claimed AZ’s shares fell to 3% in 2013 from 9% in 2010.

Dion said Eli Lilly’s market share declined from 14.3% in 2010 to 11.2% in 2013, due to decreasing sales of the company’s medication for schizophrenia and bipolar disorder.

It is claimed Ablify, an anti-psychotic drug, produced by Otsuka, will have its US patent expire in 2015, meaning the drug is predicted to lose nearly £5bn by 2019 as a result of generic medications.


Want news like this straight to your inbox?


Latest News

Plans to allow pharmacists to administer Covid-19 vaccine become law
Community pharmacists will be able to administer Covid-19 vaccines under amendments to the Human Medicines...
Serious shortage protocol for Fluoxetine 40mg capsules ends
The serious shortage protocol (SSP) issued in response to ‘significant ongoing disruption to the supply...
Plans to withdraw widely-used bipolar drug put on hold
A drug company that recently increased the price of a bipolar drug, while also proposing...